3D Medicines (HKSE:01244) Total Receivables: HK$106.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01244 3D Medicines Inc HKSE:01244
49 GF Score
Price HK$2.02
GF Value HK$3.15
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is 3D Medicines Total Receivables?

3D Medicines HKSE:01244 +3.33% 49 Total Receivables is HK$106.0 Mil as of Dec. 2025. GuruFocus rates HKSE:01244 with a GF Score™ of 49/100 and a GF Value™ of HK$3.15 (Possible Value Trap). The stock has 5 warning signs investors should review.

3D Medicines's Total Receivables for the quarter that ended in Dec. 2025 was HK$106.0 Mil.

3D Medicines Total Receivables Historical Data

* Premium members only.

The historical data trend for 3D Medicines's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3D Medicines Total Receivables Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 81.18 169.20 84.23 132.31 105.97

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 84.23 130.25 132.31 187.38 105.97
HKSE:01244
49GF Score
3D Medicines Inc HKSE:01244
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3D Medicines Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$106.0 Mil mean?
3D Medicines (HKSE:01244) has a Total Receivables of HK$106.0 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on 3D Medicines and its competitors.
Is 3D Medicines' Total Receivables too high?
3D Medicines' current Total Receivables is HK$106.0 Mil. Overall, 3D Medicines has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3D Medicines' Total Receivables compare to VRTX and REGN?
3D Medicines' Total Receivables of HK$106.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on 3D Medicines and its competitors. 3D Medicines's current Total Receivables is HK$106.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Medicines stock overvalued right now?
Based on GuruFocus' analysis, 3D Medicines (HKSE:01244) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.15, compared to a current price of HK$2.02 — trading 36% below its estimated fair value. The current Total Receivables is HK$106.0 Mil. 3D Medicines' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For 3D Medicines (HKSE:01244), the current Total Receivables is HK$106.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3D Medicines (HKSE:01244) Overvalued in 2026?

Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued. The current stock price of HK$2.02 is trading 36% below its estimated GF Value™ of HK$3.15. GuruFocus considers 3D Medicines to be Possible Value Trap.

Key valuation signals for HKSE:01244:

  • Total Receivables: HK$106.0 Mil
  • GF Value™: HK$3.15 vs. price of HK$2.02 (36% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3D Medicines Business Description

Address No. 3 and No. 5, Laiyang Road, Shandong Province, Shinan District, Qingdao, CHN
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
49GF Score

Get the complete analysis for HKSE:01244

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.02
Price
HK$3.15
GF Value